BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takagi H, Umemoto T. Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: a meta-analysis of randomized head-to-head trials. Int J Cardiol 2012;157:403-7. [PMID: 22386702 DOI: 10.1016/j.ijcard.2012.02.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Pushpakom S, Kolamunnage-dona R, Taylor C, Foster T, Spowart C, Garcia-finana M, Kemp GJ, Jaki T, Khoo S, Williamson P, Pirmohamed M. Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. Efficacy Mech Eval 2019;6:1-168. [DOI: 10.3310/eme06060] [Reference Citation Analysis]
2 Naguib YM, Samaka RM, Rizk MS, Ameen O, Motawea SM. Countering adipose tissue dysfunction could underlie the superiority of telmisartan in the treatment of obesity-related hypertension. Cardiovasc Diabetol 2021;20:70. [PMID: 33761942 DOI: 10.1186/s12933-021-01259-w] [Reference Citation Analysis]
3 Takagi H, Umemoto T; All-Literature Investigation of Cardiovascular Evidence Group. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. J Am Soc Hypertens 2014;8:578-92. [PMID: 25151319 DOI: 10.1016/j.jash.2014.05.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
4 Zidek V, Mlejnek P, Simakova M, Silhavy J, Landa V, Kazdova L, Pravenec M, Kurtz TW. Tissue-Specific Peroxisome Proliferator Activated Receptor Gamma Expression and Metabolic Effects of Telmisartan. American Journal of Hypertension 2013;26:829-35. [DOI: 10.1093/ajh/hpt019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
5 Kritsi E, Potamitis C, Durdagi S, Zoumpoulakis P, Golic Grdadolnik S, Mavromoustakos T. Molecular insights into the AT1 antagonism based on biophysical and in silico studies of telmisartan. Med Chem Res 2013;22:4842-57. [DOI: 10.1007/s00044-012-0464-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Han S, Zhang P, Wei F, Wang S. Screening active components acting on α1A adrenergic receptors from agrimony using a Sprague-Dawley rat prostate cell membrane chromatography online coupled HPLC/MS method. Anal Methods 2012;4:3351. [DOI: 10.1039/c2ay25703c] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
7 Godoy-Lugo JA, Thorwald MA, Hui DY, Nishiyama A, Nakano D, Soñanez-Organis JG, Ortiz RM. Chronic angiotensin receptor activation promotes hepatic triacylglycerol accumulation during an acute glucose challenge in obese-insulin-resistant OLETF rats. Endocrine 2021. [PMID: 34327606 DOI: 10.1007/s12020-021-02834-7] [Reference Citation Analysis]
8 Sisignano M, Steinhilber D, Parnham MJ, Geisslinger G. Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications. Drug Discovery Today 2020;25:1744-53. [DOI: 10.1016/j.drudis.2020.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Kakuta H, Kurosaki E, Niimi T, Gato K, Kawasaki Y, Suwa A, Honbou K, Yamaguchi T, Okumura H, Sanagi M, Tomura Y, Orita M, Yonemoto T, Masuzaki H. Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptor γ among Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses. J Pharmacol Exp Ther 2014;349:10-20. [DOI: 10.1124/jpet.113.211722] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]